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Despite  a century  of  research  focused  on  the development  and  implementation  of effective  control
strategies,  infection  with  the  malaria  parasite  continues  to result  in  signiﬁcant  morbidity  and  mortal-
ity  worldwide.  An  effective  malaria  vaccine  is considered  by many  to  be  the  deﬁnitive  solution.  Yet,  after
decades  of  research,  we  are  still  without  a  vaccine  that  is capable  of  inducing  robust,  long  lasting  pro-
tection  in  naturally  exposed  individuals.  Extensive  sub-unit  vaccine  development  focused  on  the  bloodaccine
hole parasite
lood stage
stage  of  the malaria  parasite  has  thus  far yielded  disappointing  results.  There  is  now  a renewed  focus  on
whole  parasite  vaccine  strategies,  particularly  as they  may  overcome  some  of  the  inherent  weaknesses
deemed  to be associated  with  the  sub-unit  approach.  This review  discusses  the  whole  parasite  vaccine
strategy  focusing  on  the  blood  stage  of  the  malaria  parasite,  with  an  emphasis  on  recent  advances  and
challenges  in  the  development  of  killed  and  live  attenuated  vaccines.
©  2015  Elsevier  Ltd. This is  an open  access  article  under  the  CC  BY  license. Introduction
Malaria infection is caused by parasites of the genus Plasmodium,
ith Plasmodium falciparum and P. vivax being the most prevalent of
he 6 species that are able to infect humans. In 2012 there were over
.4 billion people at risk of contracting malaria, over 200 million
ases and 627,000 attributable deaths [1].
There is a long history of research into the development and
mplementation of different strategies which aim to both prevent
nd treat malaria infection. These include vector control (e.g. use
f insecticide treated bed nets to reduce human-vector contact),
hemoprevention (e.g. Intermittent Preventive Treatment (IPT)
or vulnerable populations such as pregnant women and infants)
nd the prompt diagnosis and treatment of conﬁrmed cases with
ppropriate anti-malaria drugs. While these have undoubtedly con-
ributed to the progress in reducing case incidence and mortality
ates [1], a vaccine is still seen as the deﬁnitive tool to prevent
orbidity and mortality.
Despite decades of research, an effective malaria vaccineemains elusive. This is due to a number of factors including: the
omplex nature and life-cycle of the malaria parasite; its ability to
apidly evolve and evade the host immune system; and the lack
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xxonMobil Foundation.
∗ Corresponding author. Tel.: +61 7 555 29433.
∗∗ Corresponding author. Tel.: +61 7 555 29435.
E-mail addresses: d.stanisic@grifﬁth.edu.au (D.I. Stanisic),
ichael.Good@grifﬁth.edu.au (M.F. Good).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.057
264-410X/© 2015 Elsevier Ltd. This is an open access article under the CC BY license (ht(http://creativecommons.org/licenses/by/4.0/).
of understanding of what precisely mediates immunity. Numerous
sub-unit and whole parasite vaccine approaches targeting different
parasite life-cycle stages are being examined in the pursuit of an
effective vaccine. Disappointing results following the efﬁcacy test-
ing of sub-unit vaccines in clinical trials [2–4], including the most
advanced vaccine candidate, RTS,S [5], have highlighted some of the
intrinsic limitations of sub-unit vaccines that need to be addressed.
Conversely, recent promising results from the clinical testing of
radiation attenuated sporozoites [6] have re-ignited interest in the
whole parasite approach. A radiation attenuated sporozoite vaccine
must be 100% effective as even one mosquito-injected sporozoite
developing through to blood stage could result in a fulminant blood
stage infection. For a whole parasite blood stage vaccine, even a
partially effective vaccine could result in lower parasitemias and
absence of symptomatic disease in recipients. This review will focus
on recent advances in strategies to develop a whole parasite blood
stage vaccine. It will also discuss some of the major challenges.
2. Evidence for a whole parasite blood stage vaccine
approach
Historically, vaccine production has involved the isolation, inac-
tivation/attenuation and injection of the whole infectious agent.
This was facilitated by the development of methodology to culti-
vate the organisms to enable large-scale production of the killed
or live attenuated vaccines and has been successfully employed for
a number of organisms such as those causing the following dis-
eases: tuberculosis, polio, measles, mumps, rubella and varicella
(reviewed in [7]).
tp://creativecommons.org/licenses/by/4.0/).
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Table 1
Characteristics of whole organism vaccine strategies.
Type of vaccine Characteristics
Killed vaccines Advantages:
• Unable to replicate in the host.
•  Cannot revert to virulence and result in
infection
•  Cannot be transmitted to susceptible
individuals
Disadvantages:
• Most require the use of adjuvants to enhance
immunogenicity
•  May  require multiple doses to induce
protective immunity
Live attenuated vaccines Advantages:
• Able to replicate in recipient so a lower
number of parasites/fewer doses may be
required.
•  Generally associated with longer lasting
protection.
Disadvantage:
• Failure/instability of attenuation and
reversion to virulence
and testing of adjuvants appropriate for use in humans (reviewed in
[22]). Issues encountered with the selection and utilisation of these470 D.I. Stanisic, M.F. Good / 
Whole organism blood stage malaria vaccine approaches were
rst investigated using animal models in the 1940s. Both ducks and
onkeys were protected following immunisation with killed and
djuvanted Plasmodium lophurae and Plasmodium knowlesi infected
ed blood cells respectively [8,9]. Protection was also observed
sing the human malaria parasite, P. falciparum,  in Aotus monkeys
10]. These and other non-human primate studies (reviewed in
11]) involved the use of Complete Freund’s Adjuvant to enhance
he immunogenicity of the parasite. Although this adjuvant is
ncompatible with human use, killed parasites in combination
ith alternative adjuvants were unable to successfully immunise
onkeys [9]. The requirement for a human-compatible adjuvant to
nhance the immunogenicity of the parasite and the inability at that
ime to generate sufﬁcient quantities of human malaria parasites
o enable clinical efﬁcacy studies, were seen as substantial obsta-
les to furthering this vaccine approach. Although the discovery of
ow to culture P. falciparum [12] gave some impetus to the ﬁeld,
he perceived difﬁculties of this approach together with the ability
o clone and express P. falciparum recombinant proteins [13,14],
esulted in the sub-unit vaccine approach becoming the focus of
alaria vaccine development. Recently, however, the challenges
nd disappointments of sub-unit vaccines has led to a renewed
nterest in the whole parasite approach.
. Advances in whole parasite blood stage vaccine strategies
A major advantage of the whole parasite vaccine approach is
he broad array of antigens that such a vaccine presents to the
mmune system. Many are highly conserved between different par-
site strains. This helps overcome two of the issues which have
mpacted on the efﬁcacy of sub-unit vaccine candidates – immuno-
ogical non-responsiveness and antigenic polymorphism. However,
ne of the key questions for the development of a malaria vac-
ine, is what type of immune response do we need to induce to
esult in robust protection. Immunity induced by natural exposure
o the whole parasite during malaria infection is sub-optimal and
akes several years to develop; therefore a whole parasite vaccine
ust improve on naturally acquired immunity by inducing either
 different type or magnitude of immune response.
In the early 1900s, malariatherapy, which involved a protracted
lood stage malaria infection, was a recognised treatment for neu-
osyphilis. A retrospective examination of these records suggests
he induction of clinical and anti-parasite immunity during a sec-
nd blood stage infection, manifesting as a decrease in parasitemia
nd febrile episodes [15]. More recently, multiple low doses of
. falciparum parasitised red blood cells (pRBC) were adminis-
ered to malaria naïve individuals, with each infection terminated
rior to patency with anti-malaria treatment [16]. Protection in
 out of 4 volunteers was evident and was associated with the
nduction of vigorous parasite-speciﬁc cellular responses in the
bsence of detectable parasite-speciﬁc antibody, although the pos-
ibility that residual drug contributed to this protection could not
e ruled out [17]. These immune responses differed from those
hat follow a natural (patent) infection where antibody responses
re evident. Subsequent rodent studies also showed that mul-
iple sub-patent malaria infections terminated by anti-malaria
reatment could induce robust homologous and heterologous
nfection with induction of a similar antibody-independent protec-
ive immune response [18]. The results from a recent clinical study
uggest that this protective immunity may  be reliant on prolonged
xposure to the malaria parasite during multiple asexual cycles.
ultiple immunisations of sporozoites via infected mosquito bite
hile taking chloroquine prophylaxis induced immune responses
o the P. falciparum blood stage, but these responses were not
rotective [19]. It was thought that the prophylactic levels ofchloroquine present in the volunteers’ blood resulted in a short-
lived parasitemia, and this exposure to the blood stage was  not
sufﬁcient to generate protective immune responses [19]. These
results collectively suggest that persistence of the blood stage
parasite at low levels is associated with induction of protec-
tive immunity. Although the infection/drug treatment model is
not a feasible malaria vaccine approach, it does inform vaccine
development.
A number of approaches are currently being pursued to fur-
ther this strategy and develop either a killed or live, attenuated
blood stage malaria vaccine (Table 1). Each approach has its own
advantages and disadvantages, which have implications for vaccine
design.
4. Immunisation with killed blood stage parasites
As mentioned above, early work with rodents and monkeys
demonstrated that vaccination with killed parasites/parasite lysate
(including merozoites) can induce protective immunity (reviewed
in [11]), when co-administered with Complete Freund’s Adju-
vant. A more recent study investigated the protective efﬁcacy of
low doses (100 and 1000) of frozen/thawed pRBC in the adju-
vant CpG-ODN [20]. Homologous and heterologous protection was
observed following immunisation, although low grade parasitemia
was observed in vaccinated mice. Protection was dependent on
CD4+ T cells, IFN- and nitric oxide. This low dose parasite approach
was chosen based on immunological considerations with low doses
of parasites shown to induce robust T cell responses [18] without
the deletion of effector cells that has been observed with higher par-
asite doses [21]. The induction of robust, protective T cell responses
using a low dose of killed, adjuvanted parasites is very encouraging
as the feasibility of producing large numbers of parasites during
scale-up for human vaccine production is considered a limitation
of the whole parasite approach.
Further development of this strategy requires the identiﬁcationcompounds includes: limited access to novel or existing proprietary
adjuvants; unacceptable safety proﬁle of the ﬁnal formulation; and
a lack of understanding of the type of immune response that is
required.
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. Immunisation with radiation-attenuated parasites
Early studies involving vaccination of rodents with radiation-
ttenuated parasites demonstrated that protection from lethal
nfection could be induced (reviewed in [11]). More recently, the
ffectiveness of radiation-attenuated P. berghei in inducing protec-
ion against both parasitemia and experimental cerebral malaria
ECM) in susceptible mice was investigated [23]. A radiation dose
f 100 kilorad was used to generate a non-replicating, avirulent
orm of the parasite. These irradiated parasites were able to induce
rotection against high level parasitemia, severe disease and ECM
n different susceptible rodent strains following administration of
 single non-adjuvanted high parasite dose (107). Protection was
ot observed following administration of multiple low parasite
oses (103). The inﬂuence of parasite dose on degree of protec-
ion induced by irradiated parasites is in agreement with earlier
tudies (reviewed in [11]). While the degree to which irradiated
arasites are able to persist to stimulate the immune system with-
ut causing severe disease may  inﬂuence their efﬁcacy as a vaccine,
sing sub-optimal doses of irradiation in this study resulted in
. berghei parasites escaping attenuation and initiating fulminant
nfections and severe disease [23]. Enhancement of protective
mmunity may  be facilitated by the use of an avirulent parasite,
uch as the P. berghei XAT parasite (a radiation-attenuated deriva-
ive of the P. berghei NK65 strain) which is capable of initiating
 low level, self-resolving infection in immune competent mice
24]. It induces robust long-lived immunity, with recipient mice
eveloping a very low self-limiting parasitemia following lethal P.
erghei challenge. The use of an avirulent parasite generated by
rradiation in humans would however present a number of obvi-
us challenges with concerns of possible reversion to a virulent
henotype and its use in immunocompromised/immunodeﬁcient
ndividuals.
A study in the 1980s examined radiation attenuation of P. fal-
iparum, with surviving parasites demonstrating an attenuated
rowth rate, although reversion was observed following sub-
noculation into culture [25]. Although a number of studies have
xamined radiation attenuation of parasites, only recently has an
ttempt been made to characterise the cellular and molecular
asis of this attenuation method [26]. Interestingly, parasites that
urvived attenuation in this study had a normal growth proﬁle,
ith the authors suggesting that they arose from a few para-
ites that were either not affected by irradiation or were able to
elf-repair. Given the concerns related to attenuation escapees
nd reversion of attenuated parasites to a virulent form, this
bservation emphasises the need for a deeper understanding of
he mechanism of radiation attenuation to further this vaccine
pproach.
. Immunisation with chemically attenuated parasites
A novel approach that has recently been applied to the devel-
pment of a whole parasite vaccine is the use of chemicals to
ttenuate the parasite. Seco-cyclopropyl pyrrolo indole analogues
ere originally shown to have anti-malaria activity when directly
dministered to parasitemic mice [27]. Additionally, mice injected
ith treated sporozoites exhibited sterile immunity following chal-
enge [28]. It is thought that these compounds affect parasite
eplication by irreversibly alkylating parasite DNA in polyA rich
egions. These compounds are genotoxic, so their use in a vaccine
s informed by the “EU Guidelines on the limits of Genotoxic Impu-
ities” which is produced by the European Medicines Agency and
as been adopted by the Australian Therapeutic Goods Adminis-
ration. We  have demonstrated that the residual amount of free
afuramycin-A which would be present in a vaccine dose, is welle 33 (2015) 7469–7475 7471
below the limits described in these guidelines (DI Stanisic and MF
Good, unpublished data). As the chemical binds to the parasite
DNA in an irreversible manner, reversion to a virulent phenotype
is unlikely.
We  recently demonstrated that mice vaccinated with a single
dose of 106 P. chabaudi pRBC treated with 2 M of Centanamycin
or Tafuramycin-A were protected from homologous and heterolo-
gous challenge (Fig. 1) and this protection was  long-lived, lasting
up to 6 months [29]. Both parasite-speciﬁc CD4+ and CD8+ T cell
responses were induced, with protection mediated by CD4+ T cells.
Parasite-speciﬁc antibodies were not detected. Many of the anti-
genic targets of T cells are intracellular, and are not under immune
pressure so they may  be highly conserved between different Plas-
modium strains/species. The efﬁcacy data demonstrated that this
vaccine approach was  able to overcome Plasmodium strain/species
differences, possibly by inducing protective T cell responses that
targeted conserved antigens. In these mice, protection was depend-
ent on the red cell membrane remaining intact, suggesting that
this is critical for the interaction between the attenuated para-
sites and cells of the immune system. While patent parasitemia
did not develop in the vaccinated mice, parasite DNA was  detected
in the blood of vaccinated mice for over 100 days. Whether this
reﬂects live parasite or just DNA from nonviable parasites remains
to be determined, but this persistence of parasite material may
be crucial for the induction and maintenance of robust protec-
tive immunity. When blood was transferred from these vaccinated
mice to naïve BALB/c mice, the recipient mice did not develop
parasitemia, suggesting that the parasites were not viable at the
time of transfer or that viable parasites were resident in the
tissues.
We were also able to attenuate P. falciparum with these
compounds and in vitro experiments indicated that the para-
sites were not able to replicate in vitro. We  have recently
undertaken a pilot study in human volunteers to determine
the correct dose of chemical to attenuate P. falciparum so that
it does not result in a patent infection in vivo (DI Stanisic
and MF  Good, unpublished observations). Safety and immuno-
genicity of chemically attenuated parasites was also examined.
Future work will focus on optimisation of parasite dose, cha-
racterising the immune response and evaluating the protective
efﬁcacy of these chemically attenuated P. falciparum pRBC in
humans.
An alternate strategy could exploit the dependence of the
malaria parasite on the apicoplast for intraerythrocytic develop-
ment in the human host. Tetracyclines such as doxycycline exert
their anti-malarial effects on P. falciparum by inhibiting production
of proteins that are encoded by the apicoplast genome, thereby
leading to loss of apicoplast function [30]. Interestingly, these drugs
cause a delayed death phenotype in P. falciparum, i.e. the effects are
evident only in the progeny of the drug-treated parasites, allowing
for a single cycle of growth before the apicoplast fails to replicate,
ultimately resulting in parasite death. It was  recently published
that it was possible to rescue these apicoplast deﬁcient parasites
by providing them with isopentenyl pyrophosphate (IPP), a prod-
uct of isoprenoid precursor biosynthesis, a process that normally
occurs in the apicoplast [31]. Despite the loss of the apicoplast, P.
falciparum grew in vitro when they were provided with exogenous
IPP. This could be exploited for vaccine production. Large volumes
of apicoplast knockout parasites could be generated in vitro in the
presence of IPP. Following injection into the bloodstream of study
participants, in the absence of IPP, in vitro results suggest that the
parasites would continue to develop at most for an additional cycle
which would beneﬁt the vaccine’s immunogenicity. An obvious
advantage of this approach is there is very little chance of reac-
quisition of the apicoplast and therefore reversion to the wild type
phenotype.
7472 D.I. Stanisic, M.F. Good / Vaccine 33 (2015) 7469–7475
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gig. 1. Protection induced in mice by a single immunisation with 1 × 106 P. chabau
ith  (a) P. chabaudi AS or (b) P. yoelii. Crosses indicate when mice succumbed to inf
. Immunisation with genetically attenuated parasites
This strategy involves the identiﬁcation and inactivation of crit-
cal parasite metabolic processes. Targeted gene knockouts are
reated followed by functional analyses to look for attenuated
rowth of the parasite. A recent study utilised a forward genetics
pproach examining the growth of P. falciparum insertion mutants
32]. By identifying growth attenuated parasites, this strategy may
e a useful tool for identifying novel gene targets for a genetically
ttenuated vaccine.
The ﬁrst study to demonstrate that genetically attenuated blood
tage parasites could be used as a whole parasite vaccine approach,
nvolved the generation of a P. yoelii parasite with the purine
ucleoside phosphorylase (PNP) gene disrupted [33]. The enzyme
roduct is critical for purine recycling and salvage. Injection of mice
ith a single dose of 2 × 104 or 2 × 105 PNP-deﬁcient parasites
emonstrated growth attenuation compared to controls; how-
ver, average parasitemias of up to 30% were observed in the
ecipient mice. Complete protection against blood stage challenge
as observed in these mice. Although the parasitemias following
eceipt of the PNP deﬁcient parasites were much higher in mice
han would be allowed in human volunteers, this study provided
roof-of-concept for this approach.
Targeted deletion of parasite nucleoside transporter 1 (NT1), a
lasma membrane permease that mediates purine uptake, results
n a parasite that can only grow when purines are supplied in supra-
hysiological concentrations. A P. yoelii XNL NT1 knockout (Pynt1−)
as generated, injected into mice and shown to be severely growth
ttenuated [34]. Although mice that received 5,000 Pynt1− pRBC
eveloped a low-grade transient parasitemia, mice injected with
0 Pynt1− pRBC did not develop patent parasitemia following vac-
ination and exhibited sterile protection following lethal P. yoelii
M challenge. Partial protection was observed following P. berghei
hallenge. Interestingly, both  T cells and B cells were shown to
e essential for protective immunity. In this study, parasitemia was
easured by blood smear only. Given the robust protection that
as observed in the recipient mice, it would be of interest to know
f there was persistence of parasite material, as detected by PCR.
imilar to the dependence of the apicoplast deﬁcient parasites on
PP, NT1 deﬁcient P. falciparum could be grown in vitro in the pres-
nce of purines, to generate large volumes of parasites for vaccine
roduction. When injected into volunteers, the lack of sufﬁcient
urines would result in growth arrest.
Aspartic proteinases such as Plasmepsin-4 contribute to
aemoglobin digestion in the parasite; thus it was predicted for
. falciparum that disruption of these genes would result in para-
ite death. Interestingly this was not observed, with disruption of
ultiple plasmepsin genes resulting only in a mild growth defect
hen compared to the wild type parasite [35]. In a recent study the
ene for Plasmepsin-4 in P. berghei was disrupted and although it parasitised red blood cells attenuated with Tafuramycin-A. Mice were challenged
.
had only a mild effect on the development and growth rate of the
parasite, there was a major effect on the virulence of these para-
sites, compared to the parental parasite both in terms of lethality
and ability to induce experimental cerebral malaria (ECM) [36].
Protection was  observed in mice subsequently challenged with
homologous or heterologous parasites. Further work with virulence
attenuated parasites involved the sequential disruption of both the
Plasmepsin-4 and Merozoite Surface Protein-7 genes, resulting in
a parasite whose virulence attenuation was  greater than either of
the individual knockout strains [37]. Inoculation with these dou-
ble knockout parasites also resulted in a self-resolving infection
(in some mice there was  a reduction in peak parasitemia), fail-
ure to induce ECM in susceptible mice and induction of strong
homologous and heterologous protection when recipient mice
were challenged. While strong protection was induced against dis-
ease, it is likely that the administration of virulence attenuated
parasites that resulted in patent parasitemias in humans would
be associated with the development of symptoms/pathology. This
data does however provide further support for the development of
a genetically attenuated parasite vaccine.
An alternate novel strategy is to generate a virulence attenuated
parasite by directly targeting the virulence factor. This approach is
being used to generate a genetically attenuated P. falciparum par-
asite with the target being P. falciparum Erythrocyte Membrane
Protein 1 (PfEMP1) (L. Schoﬁeld and J. McCarthy, pers. comm.).
PfEMP1 is a parasite adhesion ligand that binds to host tissue
receptors on vascular endothelium (reviewed in [38]). It facilitates
sequestration of the pRBC in the microvasculature, which prevents
clearance by the spleen and contributes to the pathology of dis-
ease syndromes such as cerebral and placental malaria. It has also
been associated with immunomodulation [39,40]. This protein is
however, a highly variable surface antigen encoded by around 60
var-genes per genome, thus PfEMP1 cannot be removed by targeted
gene deletion. An alternative target is the Knob Associated His-
tidine Rich Protein (KAHRP), which is required for the formation
of the knob structures at the erythrocyte surface, where PfEMP1
is localised [41]. Without KAHRP, the pRBC cannot correctly dis-
play PfEMP1 and this prevents the adhesion of pRBC to vascular
endothelium and sequestration. As it is not possible to undertake
preclinical assessment of this approach in rodent models, following
regulatory approval these P. falciparum-KAHRP-KO parasites will be
directly evaluated in a ﬁrst-in-man dose ranging trial to establish
their safety and infectivity. This will be followed by a study to evalu-
ate the immunogenicity and protective efﬁcacy of these genetically
attenuated P. falciparum parasites.
One of the major concerns discussed in relation to the safety
of genetically attenuated parasites for human administration is the
possible reversion to the wild type genotype/phenotype as has been
seen with genetically attenuated pre-erythrocytic whole parasite
vaccines approaches. Even with the use of methodology to generate
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arasites with stable genetic attenuation, reversion of phenotype
an occur without genetic reversion to the wild type [42]. This
s discussed in more detail below. A key difference between the
enetically attenuated pre-erythrocytic and blood stage vaccine
pproaches, is that replication of the former is completely arrested
n the liver whereas for the blood stage the genetically attenu-
ted parasites should have the capacity to replicate in the blood,
lbeit in a regulated way. This is a risk associated with this type
f vaccine approach and would need to be monitored closely and
haracterised in Phase I safety trials.
. Challenges for the development and clinical evaluation
f whole parasite blood stage malaria vaccines
Production of a whole parasite blood stage vaccine presents a
umber of challenges that must be considered in the development
athway (Table 2). Some are unique to the blood stage approach due
o the use of human blood products in the manufacturing process
nd/or ﬁnal vaccine formulation. Others are inherent to vaccine
esign/development and have precedent in the production of other
hole organism vaccine approaches, e.g. the irradiated sporozoite
accine. Below, we discuss some of the challenges and possible
olutions.
. Regulatory and safety considerations
The use of human erythrocytes to grow the malaria parasite dur-
ng the manufacturing process and/or the ﬁnal formulation raises
oncerns regarding the possible contamination of the vaccine with
nfectious adventitious agents. Improved methodologies for donor
nd blood screening in recent years have decreased the likelihood of
his occurring. A reputable source of transfusion compatible human
lood products is essential, ensuring that collection and screening
f these products follows current regulatory guidelines. Related to
his is the source of malaria parasite that is used to initially “seed”
he vaccine cultures. We  have addressed this by the use of a deﬁned
alaria parasite cell bank grown at Good Manufacturing Practices
GMP) standard that has undergone rigorous screening in accor-
ance with regulatory guidelines [43].
During the production of genetically attenuated parasites, drug
esistance markers are inserted into the genome to allow for selec-
ion of the transfected gene knock-out parasites. For progression
nto human clinical studies, these drug resistance genes mark-
rs must be removed to address regulatory concerns relating to
he use of genetically attenuated organisms. Use of the Cre/Lox or
LP/FRT recombinase technologies allows the precise, repeated and
equential removal of all drug resistance genes from gene-targeted
arasites [44,45] and this is being applied to the development of
lasmodium falciparum genetically attenuated blood-stage para-
ites (L. Schoﬁeld and J. McCarthy, pers. comm.).
Possible reversion and under-attenuation need to be considered
hen developing live, attenuated vaccines. For genetically attenu-
ted parasites, reversion can be addressed by utilising methodology
o disrupt candidate genes to ensure that mutants cannot revert
o the wild type genotype. Single crossover recombination, which
nly disrupts the targeted gene, can lead to reversion via the spon-
aneous removal of the integrated plasmid. By targeting candidate
enes using double crossover recombination, the gene of interest
s replaced and this results in the loss of the gene sequence thereby
reventing reversion. Despite this, reversion of parasite phenotype
an occur without genetic reversion to wild type. Ideally, to ensure
omplete attenuation, it may  be necessary to perform multiple
ene deletions that regulate independent biological processes, as
as been undertaken with pre-erythrocytic genetically attenuated
accine approaches. A consideration for the clinical evaluation ofe 33 (2015) 7469–7475 7473
these vaccines is the need for a genetic marker that can distinguish
the vaccine parasite from any naturally acquired infection and a
deﬁned drug sensitivity proﬁle of the vaccine parasites, in the event
that a vaccine-derived infection requires drug treatment. For other
types of attenuated vaccines, e.g. chemically or drug-attenuated
parasites, while in vitro work can provide preliminary data on
chemical/drug doses that will adequately attenuate the parasite,
ultimately this must be examined and conﬁrmed through rigorous
testing in clinical pilot studies and Phase I safety trials. An addi-
tional consideration for the eventual deployment of live attenuated,
vaccines is their use in immunocompromised/immunodeﬁcient
individuals. This will need to be addressed in different popu-
lations once vaccine efﬁcacy has been established in healthy
individuals.
The presence of human erythrocytes in the ﬁnal vaccine product
has raised concerns regarding the possible induction of antibod-
ies against red blood cell surface antigens, e.g. those of the ABO
and Rh blood group systems. Low doses of P. falciparum infected
red blood cells (≤30,000) have been administered to 225 partici-
pants in experimental malaria infections (DI Stanisic and MF Good,
unpublished data; J. McCarthy, pers. comm.) and seroconversion to
donor red blood cell antigens has not been observed. These inoc-
ula contain >95% uninfected red blood cells (uRBC) so the potential
antigenicity of the red blood cells is a consideration. We  and others
have addressed this, in part, by the use of universal donor blood
group O Rh negative red blood cells. Studies conducted to-date
indicate that administration of a low dose of O Rh negative red
blood cells is not associated with seroconversion to donor red cell
antigens. If larger numbers of pRBC are required in a vaccine dose,
enrichment of these away from the uRBC for the ﬁnal vaccine for-
mulation may  be necessary.
10. Manufacturing, storage and delivery considerations
The requirement for large volumes of culture (and the associated
human blood components) as a source of malaria parasites to man-
ufacture a whole parasite vaccine at scale, is often seen as a major
limitation associated with this approach. We  and others have suc-
cessfully cultured P. falciparum at GMP  standard and administered
it to volunteers and this should be feasible for a low dose vaccine
[43]. This may  be a limiting factor for vaccines that require a large
number of parasites to induce protective immunity.
As mentioned earlier, while the killed vaccine approach was
superior in its ability to induce protection with as few as 100 pRBC,
this was dependent on the presence of a potent Th1 adjuvant. Gen-
erally, human vaccine development has been impacted by the lack
of potent, accessible human compatible adjuvants. Further devel-
opment of this approach will require the identiﬁcation and testing
of an appropriate Th1 adjuvant.
It is likely that most live, attenuated vaccines will need to
be administered intravenously. This method of delivery is being
used successfully for controlled human malaria infection studies
to administer sporozoites [46]. Portable vein visualisation devices,
e.g. the “Accuvein” can be used if veins are difﬁcult to ﬁnd.
Unique challenges are associated with the deployment of a
live, attenuated vaccine that requires integrity of the erythro-
cyte for efﬁcacy. Thus far, our experience with the production
of a chemically attenuated blood stage vaccine in pilot studies
has involved the culture, attenuation and direct administration of
live, fresh malaria parasites. This production strategy is not feasi-
ble for vaccine deployment. We  and others are working towards
the development of alternate formulation/delivery strategies, e.g. a
cryopreserved form of the vaccine that can be rapidly thawed on
site and administered. The logistics and practical considerations
for liquid nitrogen transport and storage have been extensively
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Table  2
Key challenges for the production and clinical evaluation of a whole parasite blood stage malaria vaccine.
Challenge Problem Action
The use of human blood products (e.g.
red blood cells) in the manufacturing
process/ﬁnal vaccine formulation.
Possible contamination with infectious
adventitious agents.
Screening of donors and blood products according to current
region-speciﬁc regulatory guidelines.
Use of transfusion compatible human blood products collected and
screened according to current region-speciﬁc regulatory guidelines.
Use of a deﬁned malaria cell bank that has been grown at Good
Manufacturing Practices Standard and has undergone rigorous
screening by a reputable supplier according to current region-speciﬁc
regulatory guidelines
Alloimmunisation (induction of antibodies
against red blood cell antigens).
Use of Blood Group O Rh negative red blood cells.
Limit the number of total red blood cells in a vaccine dose. This could
be  accomplished by enriching parasitised red blood cells away from
uninfected red blood cells.
Use of a parasite stage, e.g. merozoites that can be separated away
from the red blood cell membrane. Note: Preliminary data has
demonstrated that merozoites require the addition of an adjuvant to
induce strong protective immunity.c
The  use of live attenuated parasites in
the vaccine.
Possible underattenuation/reversion of
attenuated parasites to wild type.
Development of robust attenuation methodology. Preclinical in vitro
and in vivo assessment of attenuation (where possible).
Utilising appropriate methodology to replace rather than disrupt gene
of  interest.
Perform multiple deletions of genes that regulate independent
biological processes.
Identiﬁcation of a genetic marker to distinguish the vaccine parasite
from a naturally acquired infection.
Deﬁned drug sensitivity proﬁle of the vaccine parasite in the event
that a vaccine-derived infection requires drug treatment.
The use of drug resistance markers to select for
gene knock-out parasites in the production of
genetically attenuated parasites.
Removal of drug resistance markers according to appropriate
methodology.
The  use of killed parasites in the
vaccine.
The requirement for a potent human
compatible Th1 adjuvant to induce robust
immunity.
Identiﬁcation and testing of novel human compatible adjuvants.
Manufacturing, storage and
deployment of vaccine in malaria
endemic areas.
Manufacture of parasites at scale may  require
large volumes of culture for the required
number of parasites.
Perform parasite dose ranging studies to identify the lowest dose of
parasite required for protective efﬁcacy.
The requirement for intact red blood cells in
te
s for t
reas.
Development of a cryopreserved form of the vaccine that can be
a
s
1
a
s
i
t
p
w
a
f
t
h
p
a
a
t
t
s
D
a
W
u
vthe vaccine and the lack of appropria
facilities in which to culture parasite
vaccine on site in malaria endemic a
nalysed and developed for the distribution of the attenuated
porozoite vaccine [47].
1. Conclusion
Modern whole organism vaccine strategies provide hope that
 highly effective malaria vaccine may  yet be feasible. Thus far,
ub-unit vaccine candidates have performed below expectations
n malaria endemic areas, which may  in part be due to variation in
he antigens that are included in the vaccine compared with those
resent in circulating strains. One of the major advantages of the
hole parasite vaccine approach is the broad array of antigens that
re presented-many of which would be conserved between dif-
erent parasite strains. Pre-clinical data provide proof-of-concept
hat robust immunity may  be induced to both homologous and
eterologous strains and species of Plasmodium using the whole
arasite blood stage strategy. Whole parasite blood stage vaccine
pproaches can be broadly grouped into whole, killed and live,
ttenuated vaccines. Whole, killed vaccines require the identiﬁca-
ion and use of a suitable human-compatible adjuvant. Reversion
o virulence and incomplete attenuation need to be carefully con-
idered and addressed when developing live, attenuated vaccines.
espite these are technical and safety challenges, transition of these
pproaches into early phase clinical trials should occur quickly.
ith the ability to undertake challenge studies with deﬁned strains
sing sporozoites or blood stage parasites, the efﬁcacy of these
accines will soon be known.he
rapidly thawed and administered on site.
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